Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab

Table 1 Results and characteristics of the 14 patients with HSR from the retrospective cohort and the 11 patients from the prospective cohort. In bold, positive results for each test

Case	Gender	Age (years)	HSR delay after cetuximab infusion (min)	Severity grade ^a	Increased tryptase^b and/or histamine	ELISA (cut-off > 29 EAU)	FEIA (cut-off ≥ 0.35 kU_A/L)
Retrospective cohort results
P1	M	57	15	1	ND	147	< 0.1
P2	F	43	15	1	ND	80	< 0.1
P3	M	58	ND	2	no	3	0.52
P4	M	60	40	2	yes	45	0.72
P5	F	54	ND	2	ND	5	< 0.1
P6	M	79	20	2	ND	16	< 0.1
P7	M	64	5	3	yes	70	0.53
P8	F	54	5	3	yes	42	0.73
P9	M	59	5	3	yes	105	1.12
P10	M	53	25	3	yes	15	1.80
P11	M	62	15	3	yes	31	3.34
P12	M	64	10	3	ND	60	< 0.1
P13	M	60	10	4	ND	40	2.40
P14	M	69	5	4	ND	> 3000	22.6
Prospective cohort results
P15	M	73	35	1	ND	9	< 0.1
P16	M	55	25	2	ND	2.5	0.53
P17	M	74	15	2	ND	39	0.23
P18	M	48	15	2	yes	35	< 0.1
P19	M	65	30	2	yes	4	< 0.1
P20	F	60	15	3	yes	134	6.93
P21	M	50	15	3	ND	490	3.53
P22	M	56	20	3	no	55	0.23
P23	M	68	40	3	yes	15	< 0.1
P24	F	81	ND	3	no	< 3	< 0.1
P25	M	81	< 1	4	ND	480	5.63

Abbreviations: EAU IgE Arbitrary Units, ELISA Enzyme Linked Immunosorbent Assay, F Female, FEIA Fluoroenzyme-Immunoassy, HSR Hypersensitivity reaction, M Male, min minutes, ND Not determined, P Patient
^a Ring and Messmer scale [18].
^b Increased tryptase defined as ≥ 1.2 basal value + 2 µg.L^-1 [19].

ISSN: 1471-2407